A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib.

Trial Profile

A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Linsitinib (Primary)
  • Indications Liver cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 21 Dec 2011 Actual patient number (23) added as reported by ClinicalTrials.gov.
    • 21 Dec 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Company added in the association field and additional lead trial center identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top